Title: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Authors: Monk, Bradley J ×
Poveda, Andrés
Vergote, Ignace
Raspagliesi, Francesco
Fujiwara, Keiichi
Bae, Duk-Soo
Oaknin, Ana
Ray-Coquard, Isabelle
Provencher, Diane M
Karlan, Beth Y
Lhommé, Catherine
Richardson, Gary
Rincón, Dolores Gallardo
Coleman, Robert L
Herzog, Thomas J
Marth, Christian
Brize, Arija
Fabbro, Michel
Redondo, Andrés
Bamias, Aristotelis
Tassoudji, Marjan
Navale, Lynn
Warner, Douglas J
Oza, Amit M #
Issue Date: Jul-2014
Publisher: Lancet Pub. Group
Series Title: The Lancet Oncology vol:15 issue:8 pages:799-808
Article number: 10.1016/S1470-2045(14)70244-X
Abstract: Angiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of angiopoietins 1 and 2 to the Tie2 receptor, and thereby inhibits angiogenesis. We aimed to assess whether the addition of trebananib to single-agent weekly paclitaxel in patients with recurrent epithelial ovarian cancer improved progression-free survival.
ISSN: 1470-2045
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science